Scientists Reprogrammed a Probiotic to Attack IBD Inflammation From Inside the Gut

A team of researchers has reprogrammed one of the most studied probiotic bacteria on Earth to secrete a targeted anti-inflammatory molecule directly inside the inflamed gut, at least in mice. The study, published in Frontiers in Immunology, is early-stage and has not yet been tested in humans, but it demonstrates a strategy that sidesteps some of the thorniest problems in inflammatory bowel disease treatment.

Why Current Anti-TNF-alpha Therapies Fall Short

Inflammatory bowel disease affects an estimated 2.4 to 3.1 million people in the United States alone, and its prevalence keeps climbing. The condition's two main forms, Crohn's disease and ulcerative colitis, are both driven in large part by tumor necrosis factor-alpha (TNF-alpha), a signaling protein that triggers and sustains gut inflammation. Anti-TNF-alpha biologics have been confirmed effective in randomized controlled trials, but they are delivered systemically, meaning the drug circulates through the entire body rather than concentrating where it is needed. That broad exposure raises the risk of infection, blunts the immune system's ability to fight tumors and pathogens, and produces only modest concentrations at the intestinal mucosa where inflammation actually lives.

How EcN-MT1 Delivers Nanobodies at the Source

The research team built their approach around Escherichia coli Nissle 1917, a nonpathogenic probiotic strain that has been used clinically for over a century and is already known to support intestinal barrier integrity, modulate the local immune environment, and inhibit pathogenic bacteria. E. coli Nissle 1917's well-characterized probiotic properties made it an appealing chassis for engineering: it colonizes the gut reliably and its genetics are well understood.

Instead of a conventional antibody, the researchers chose a nanobody, a single-domain antibody fragment derived from the heavy-chain-only antibodies found in camelids. Nanobodies offer distinct advantages over full-sized monoclonal antibodies: they are roughly ten times smaller, fold stably in reducing environments like the gut, and can be produced by bacteria. The team's nanobody, called MT1, was designed to bind and neutralize TNF-alpha.

To get the bacterium to secrete MT1 rather than just produce it internally, the researchers screened five different signal peptides, short amino acid sequences that direct proteins toward the cell membrane for export. The alpha-hemolysin (HlyA) secretion system produced the highest yield: 4.6 mg of nanobody per liter of bacterial culture. They also compared two strategies for housing the nanobody gene inside the bacterium, a plasmid (a small circular piece of DNA that replicates independently) versus CRISPR-Cas9-mediated integration directly into the chromosome. The plasmid approach won on both yield and growth rate, without compromising the bacterium's viability. The resulting engineered strain is called EcN-MT1.

MT1 Nanobody Binding Affinity and Anti-Inflammatory Activity

Before moving to animals, the team used molecular dynamics simulations to confirm that MT1's complementarity-determining regions, the loops that physically grip the target protein, remained stable when bound to murine TNF-alpha. Binding affinity measured by ELISA came in at an EC50 of 27.9 nM, meaning a relatively small amount of nanobody was sufficient to saturate available TNF-alpha. In cell culture experiments using LPS-stimulated macrophages, MT1 potently suppressed the mRNA expression of both Tnf and Il1b, two of the key inflammatory signals elevated in IBD. The role of TNF-alpha in driving intestinal inflammation has been extensively characterized, and hitting it locally with a molecule this small is the central bet the study makes.

Mouse Colitis Results: Reduced Damage, Restored Microbiome

The therapeutic test used a dextran sulfate sodium (DSS) model of colitis in mice, a standard preclinical setup in which DSS is added to drinking water to chemically damage the intestinal lining and trigger inflammation resembling human IBD. Oral administration of EcN-MT1 significantly reduced weight loss and improved disease activity index scores compared to untreated colitic mice. Colon length, which shortens as inflammation progresses, was better preserved in the EcN-MT1 group. Histopathological examination of colon tissue showed less mucosal ulceration, less crypt loss, and fewer infiltrating immune cells. Colonic mRNA levels of both Tnf and Il1b were lower in treated animals.

Perhaps as notable as the anti-inflammatory effects was the impact on the gut microbiome. DSS colitis disrupts microbial diversity and enriches pro-inflammatory bacteria, a state called dysbiosis. EcN-MT1 treatment restored microbial diversity and enriched bacterial taxa associated with butyrate production and intestinal barrier reinforcement, two features that support mucosal healing. This dual action, direct cytokine neutralization combined with microbiome rebalancing, is what the authors describe as a distinguishing feature of the single-strain platform.

Open Questions Before This Approach Reaches Humans

This is a mouse study with all the limitations that entails. DSS colitis is a useful but imperfect model: it does not fully capture the chronic, relapsing nature of human Crohn's disease or the immune complexity of ulcerative colitis in a human host. The plasmid-based expression system also raises practical questions for clinical translation, since plasmids without selection pressure can be lost over bacterial generations, and regulatory agencies scrutinize antibiotic-resistance markers often used to maintain plasmids. Long-term colonization dynamics, dosing schedules, and potential immune responses to the nanobody or the engineered bacteria have not yet been studied. The researchers acknowledge these as areas requiring further work before human trials could be considered.

What the study does establish is proof of concept: a single, orally delivered bacterial strain can be engineered to produce and secrete a functional anti-cytokine nanobody, reduce measurable inflammation in a colitis model, and simultaneously nudge the microbial ecosystem toward a healthier state. Whether that translates into a safe and effective therapy for the millions of people managing IBD remains to be seen, but the early data gives the approach genuine credibility.

Evidence rating

INVESTIGATIONAL — 78/100

Caveats:

• All efficacy data come from a mouse model of colitis — no human trials have been conducted.
• Funding was not disclosed by the authors, so independent verification of the research context is not possible.
• The engineered strain carries a plasmid-based expression system; long-term stability and safety in humans remain untested.
• Results have not been independently replicated in a separate laboratory or species.

Preclinical murine study using a DSS-induced colitis model. Demonstrates a step-by-step mechanism from engineered probiotic secretion to local TNF-α neutralization to reduced histological damage and microbiota restoration, but all findings are limited to animal data. No human trials have been conducted, and the results have not been independently replicated.

References

1. Q Zhu, S Feng, Z Yan, Z Wang, X Huang, C Sun… (2026). Engineered Escherichia Coli Nissle 1917 Secreting ANTI-TNF-Α Nanobody as a SINGLE-STRAIN Live Biotherapeutic for Inflammatory Bowel Disease. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1865862
2. IBD Facts and Stats – CDC. cdc.gov. https://www.cdc.gov/ibd/data-statistics.htm
3. The role of TNFalpha in ulcerative colitis – PubMed. NIH. https://pubmed.ncbi.nlm.nih.gov/17696191/
4. Franco Scaldaferri, Viviana Gerardi, Francesca Mangiola, et al. (2016). Role and mechanisms of action ofEscherichia coliNissle 1917 in the maintenance of remission in ulcerative colitis patients: An update. World Journal of Gastroenterology. https://doi.org/10.3748/wjg.v22.i24.5505
5. NANOBODIES®: A Review of Generation, Diagnostics and Therapeutics – PMC. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074476/
6. Study of tumor necrosis factor receptor in the inflammatory bowel disease – PMC – NIH. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900010/